Biogen (BIIB) option implied volatility low into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE

March 21, 2019 7:38 AM

Biogen (NASDAQ: BIIB) March weekly and April call option implied volatility is at 27 compared to its 52-week range of 21 to 45 into the company and partner Eisai (ESALY) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE.

Categories

Corporate News FDA Options Trader Talk

Next Articles